Abstract

Adenosine deaminases acting on RNA (ADARs) catalyze the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) and thereby potentially alter the information content and structure of cellular RNAs. Notably, although the overwhelming majority of such editing events occur in transcripts derived from Alu repeat elements, the biological function of non-coding RNA editing remains uncertain. Here, we show that mutations in ADAR1 (also known as ADAR) cause the autoimmune disorder Aicardi-Goutières syndrome (AGS). As in Adar1-null mice, the human disease state is associated with upregulation of interferon-stimulated genes, indicating a possible role for ADAR1 as a suppressor of type I interferon signaling. Considering recent insights derived from the study of other AGS-related proteins, we speculate that ADAR1 may limit the cytoplasmic accumulation of the dsRNA generated from genomic repetitive elements.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Accessions

NCBI Reference Sequence

References

  1. 1.

    & Aicardi-Goutières syndrome: an important Mendelian mimic of congenital infection. Dev. Med. Child Neurol. 50, 410–416 (2008).

  2. 2.

    et al. Intrathecal synthesis of interferon-α in infants with progressive familial encephalopathy. J. Neurol. Sci. 84, 201–208 (1988).

  3. 3.

    et al. Mutations in the gene encoding the 3′-5′ DNA exonuclease TREX1 cause Aicardi-Goutières syndrome at the AGS1 locus. Nat. Genet. 38, 917–920 (2006).

  4. 4.

    et al. Mutations in genes encoding ribonuclease H2 subunits cause Aicardi-Goutières syndrome and mimic congenital viral brain infection. Nat. Genet. 38, 910–916 (2006).

  5. 5.

    et al. Mutations involved in Aicardi-Goutières syndrome implicate SAMHD1 as regulator of the innate immune response. Nat. Genet. 41, 829–832 (2009).

  6. 6.

    et al. HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase. Nature 480, 379–382 (2011).

  7. 7.

    et al. Clinical and molecular phenotype of Aicardi-Goutières syndrome. Am. J. Hum. Genet. 81, 713–725 (2007).

  8. 8.

    et al. Heterozygous mutations in TREX1 cause familial chilblain lupus and dominant Aicardi-Goutières syndrome. Am. J. Hum. Genet. 80, 811–815 (2007).

  9. 9.

    et al. Expanding the phenotypic spectrum of lupus erythematosus in Aicardi-Goutières syndrome. Arthritis Rheum. 62, 1469–1477 (2010).

  10. 10.

    et al. A de novo p.Asp18Asn mutation in TREX1 in a patient with Aicardi-Goutières syndrome. Am. J. Med. Genet. A. 152A, 2612–2617 (2010).

  11. 11.

    , , & Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell 134, 587–598 (2008).

  12. 12.

    et al. Autoimmunity initiates in nonhematopoietic cells and progresses via lymphocytes in an interferon-dependent autoimmune disease. Immunity 36, 120–131 (2012).

  13. 13.

    et al. The cytosolic exonuclease TREX1 inhibits the innate immune response to human immunodeficiency virus type 1. Nat. Immunol. 11, 1005–1013 (2010).

  14. 14.

    et al. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 474, 654–657 (2011).

  15. 15.

    et al. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 474, 658–661 (2011).

  16. 16.

    et al. SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates. Nat. Immunol. 13, 223–228 (2012).

  17. 17.

    et al. Automated genome-wide visual profiling of cellular proteins involved in HIV infection. J. Biomol. Screen. 16, 945–958 (2011).

  18. 18.

    , & An autoimmune disease prevented by anti-retroviral drugs. Retrovirology 8, 91 (2011).

  19. 19.

    , , & ADAR1 is essential for the maintenance of hematopoiesis and suppression of interferon signaling. Nat. Immunol. 10, 109–115 (2009).

  20. 20.

    Type I interferonopathies: a novel set of inborn errors of immunity. Ann. NY Acad. Sci. 1238, 91–98 (2011).

  21. 21.

    , , & RNA editing by mammalian ADARs. Adv. Genet. 73, 87–120 (2011).

  22. 22.

    & Human RNA-specific adenosine deaminase ADAR1 transcripts possess alternative exon 1 structures that initiate from different promoters, one constitutively active and the other interferon inducible. Proc. Natl. Acad. Sci. USA 96, 4621–4626 (1999).

  23. 23.

    et al. A Z-DNA binding domain present in the human editing enzyme, double-stranded RNA adenosine deaminase. Proc. Natl. Acad. Sci. USA 94, 8421–8426 (1997).

  24. 24.

    et al. Mutations of the RNA-specific adenosine deaminase gene (DSRAD) are involved in dyschromatosis symmetrica hereditaria. Am. J. Hum. Genet. 73, 693–699 (2003).

  25. 25.

    et al. Mutational spectrum of the ADAR1 gene in dyschromatosis symmetrica hereditaria. Arch. Dermatol. Res. 302, 469–476 (2010).

  26. 26.

    et al. Dystonia, mental deterioration, and dyschromatosis symmetrica hereditaria in a family with ADAR1 mutation. Mov. Disord. 21, 1510–1513 (2006).

  27. 27.

    et al. Dyschromatosis symmetrica hereditaria associated with neurological disorders. J. Dermatol. 35, 662–666 (2008).

  28. 28.

    et al. Editing independent effects of ADARs on the miRNA/siRNA pathways. EMBO J. 28, 3145–3156 (2009).

  29. 29.

    et al. Requirement of dimerization for RNA editing activity of adenosine deaminases acting on RNA. J. Biol. Chem. 278, 17093–17102 (2003).

  30. 30.

    et al. Chilblains as a diagnostic sign of Aicardi-Goutières syndrome. Neuropediatrics 41, 18–23 (2010).

  31. 31.

    et al. Six novel mutations of the ADAR1 gene in patients with dyschromatosis symmetrica hereditaria: histological observation and comparison of genotypes and clinical phenotypes. J. Dermatol. 35, 395–406 (2008).

  32. 32.

    et al. Systematic identification of abundant A-to-I editing sites in the human transcriptome. Nat. Biotechnol. 22, 1001–1005 (2004).

  33. 33.

    , & Widespread A-to-I RNA editing of Alu-containing mRNAs in the human transcriptome. PLoS Biol. 2, e391 (2004).

  34. 34.

    , , & A survey of RNA editing in human brain. Genome Res. 14, 2379–2387 (2004).

  35. 35.

    et al. Widespread RNA editing of embedded Alu elements in the human transcriptome. Genome Res. 14, 1719–1725 (2004).

  36. 36.

    & ADAR editing in double-stranded UTRs and other noncoding RNA sequences. Trends Biochem. Sci. 35, 377–383 (2010).

  37. 37.

    , & Competition between ADAR and RNAi pathways for an extensive class of RNA targets. Nat. Struct. Mol. Biol. 18, 1094–1101 (2011).

  38. 38.

    et al. ADAR1 RNA deaminase limits short interfering RNA efficacy in mammalian cells. J. Biol. Chem. 280, 3946–3953 (2005).

  39. 39.

    & Double-stranded RNAs containing multiple IU pairs are sufficient to suppress interferon induction and apoptosis. Nat. Struct. Mol. Biol. 17, 1043–1050 (2010).

  40. 40.

    , , & An ADAR that edits transcripts encoding ion channel subunits functions as a dimer. EMBO J. 22, 3421–3430 (2003).

  41. 41.

    et al. Development of potential pharmacodynamic and diagnostic markers for anti–IFN-α monoclonal antibody trials in systemic lupus erythematosus. Hum. Genomics Proteomics 2009, 374312 (2009).

  42. 42.

    et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann. Rheum. Dis. 70, 2029–2036 (2011).

  43. 43.

    et al. Inositol hexakisphosphate is bound in the ADAR2 core and required for RNA editing. Science 309, 1534–1539 (2005).

  44. 44.

    et al. Clustal W and Clustal X version 2.0. Bioinformatics 23, 2947–2948 (2007).

  45. 45.

    & Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 234, 779–815 (1993).

  46. 46.

    , & KING (Kinemage, Next Generation): a versatile interactive molecular and scientific visualization program. Protein Sci. 18, 2403–2409 (2009).

  47. 47.

    , , & Asparagine and glutamine: using hydrogen atom contacts in the choice of side-chain amide orientation. J. Mol. Biol. 285, 1735–1747 (1999).

  48. 48.

    et al. Visualizing and quantifying molecular goodness-of-fit: small-probe contact dots with explicit hydrogen atoms. J. Mol. Biol. 285, 1711–1733 (1999).

  49. 49.

    , , & The penultimate rotamer library. Proteins 40, 389–408 (2000).

  50. 50.

    , & Crystal structure of Staphylococcus aureus tRNA adenosine deaminase TadA in complex with RNA. Nat. Struct. Mol. Biol. 13, 153–159 (2006).

  51. 51.

    et al. The solution structure of the ADAR2 dsRBM-RNA complex reveals a sequence-specific readout of the minor groove. Cell 143, 225–237 (2010).

  52. 52.

    et al. Crystal structure of the Zα domain of the human editing enzyme ADAR1 bound to left-handed Z-DNA. Science 284, 1841–1845 (1999).

Download references

Acknowledgements

We sincerely thank the participating families for the use of genetic samples and clinical information. We thank B. Hamel, H. Brunner and other clinical collaborators for contributing samples not included in the current manuscript, A.P. Jackson for highlighting the presence of intracranial calcification in individuals with DSH with a p.Gly1007Arg alteration in ADAR1 and D.B. Stetson and D.T. Bonthron for critical reading of the manuscript. D.B. Stetson (University of Washington) provided the ADAR1 constructs used in the editing assays. We thank the NHLBI GO Exome Sequencing Project and its ongoing studies that produced and provided exome variant calls for comparison: the Lung GO Sequencing Project (HL-102923), the Women's Health Initiative (WHI) Sequencing Project (HL-102924), the Broad GO Sequencing Project (HL-102925), the Seattle GO Sequencing Project (HL-102926) and the Heart GO Sequencing Project (HL-103010). Y.J.C. acknowledges the Manchester National Institute for Health Research (NIHR) Biomedical Research Centre. The research leading to these results has received funding from the European Union's Seventh Framework Programme (FP7/2007-2013) under grant agreement 241779 and from the Great Ormond Street Hospital Children's Charity.

Author information

Affiliations

  1. Manchester Academic Health Science Centre, University of Manchester, Genetic Medicine, Manchester, UK.

    • Gillian I Rice
    • , Paul R Kasher
    • , Gabriella M A Forte
    • , Marcin Szynkiewicz
    • , Jonathan E Dickerson
    • , Sanjeev S Bhaskar
    • , Massimiliano Zampini
    • , Tracy A Briggs
    • , Emma M Jenkinson
    •  & Yanick J Crow
  2. Medical Research Council (MRC) Human Genetics Unit, Institute of Genetics and Molecular Medicine (IGMM), University of Edinburgh, Edinburgh, UK.

    • Niamh M Mannion
    • , Sam M Greenwood
    • , Liam P Keegan
    •  & Mary A O'Connell
  3. Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA.

    • Carlos A Bacino
  4. Department of Developmental Neuroscience, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Stella Maris, Pisa, Italy.

    • Roberta Battini
  5. Laboratory of Molecular Medicine, Department of Neuroscience, Bambino Gesù Children's Research Hospital, Rome, Italy.

    • Enrico Bertini
  6. University College London (UCL) Institute of Child Health, London, UK.

    • Paul A Brogan
  7. Birmingham Women's National Health Service (NHS) Foundation Trust, Birmingham, UK.

    • Louise A Brueton
  8. Department of Child Neurology and Psychiatry, A Manzoni Hospital, Lecco, Italy.

    • Marialuisa Carpanelli
  9. Nutrition and Metabolism Unit, Hôpital Universitaire des Enfants Reine Fabiola (ULB), Brussels, Belgium.

    • Corinne De Laet
  10. Reference Center of Metabolic Diseases, Hôpital Necker–Enfants Malades, Paris Descartes University, Paris, France.

    • Pascale de Lonlay
  11. Pediatric Neurology Unit, Hospital Vall d'Hebron, Barcelona, Spain.

    • Mireia del Toro
  12. Neuropediatric Unit, Assistance Publique–Hôpitaux de Paris (AP-HP), Paris V Descartes University, Necker Hospital, Paris, France.

    • Isabelle Desguerre
  13. Mother and Child Department, Unit of Child Neurology and Psychiatry, Civil Hospital, University of Brescia, Brescia, Italy.

    • Elisa Fazzi
  14. Department of Neurology, Hospital Sant Joan de Déu (HSJD), Barcelona, Spain.

    • Àngels Garcia-Cazorla
  15. El Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER), Instituto de Salud Carlos III, Madrid, Spain.

    • Àngels Garcia-Cazorla
  16. Department of Medical Genetics, Oslo University Hospital, National Hospital, Oslo, Norway.

    • Arvid Heiberg
  17. Department of Dermatology, Yamagata University Faculty of Medicine, Yamagata, Japan.

    • Masakazu Kawaguchi
    •  & Tamio Suzuki
  18. Department of Neurology, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.

    • Ram Kumar
  19. General Neurology & Complex Motor Disorders Service, Evelina Children's Hospital, Guy's & St. Thomas' NHS Foundation Trust, London, UK.

    • Jean-Pierre S-M Lin
  20. Department of Neurosciences and Behavior Sciences, School of Medicine of Ribeirão Preto, University of São Paulo, São Paulo, Brazil.

    • Charles M Lourenco
    •  & Wilson Marques Jr
  21. North East Thames Regional Genetics Service, Great Ormond Street Hospital for Children, London, UK.

    • Alison M Male
  22. Département de Génétique et Cytogénétique, AP-HP, Groupe Hospitalier Pitié–Salpêtrière, Paris, France.

    • Cyril Mignot
  23. Service de Neuropédiatrie, AP-HP, Hopital Armand Trousseau, Paris, France.

    • Cyril Mignot
  24. Centre de Déficience des Déficiences Intellectuelles de Causes Rares, Paris, France.

    • Cyril Mignot
  25. Child Neurology and Psychiatry Unit, IRCCS C Mondino National Institute of Neurology Foundation, Pavia, Italy.

    • Ivana Olivieri
    •  & Simona Orcesi
  26. Department of Neurology, Great Ormond Street Hospital, London, UK.

    • Prab Prabhakar
    •  & Robert A Robinson
  27. Section of Child Neurology, Women and Children's Division, Oslo University Hospital, Oslo, Norway.

    • Magnhild Rasmussen
  28. Service de Virologie, Paris Descartes University, AP-HP, Hopital Cochin St. Vincent de Paul, Paris, France.

    • Flore Rozenberg
    •  & Pierre Lebon
  29. Department of Neurology, Children's National Medical Center, Washington, DC, USA.

    • Johanna L Schmidt
    •  & Adeline Vanderver
  30. Institute of Medical Genetics, University of Zurich, Schwerzenbach, Switzerland.

    • Katharina Steindl
  31. Victorian Clinical Genetics Services, Murdoch Children's Research Institute, Royal Children's Hospital, Melbourne, Victoria, Australia.

    • Tiong Y Tan
  32. Paediatric Department, Nobles Hospital, Strang, UK.

    • William G van der Merwe
  33. Neurology Department, Royal Manchester Children's Hospital, Manchester, UK.

    • Grace Vassallo
  34. North West Thames Regional Genetics Service, North West London Hospitals NHS Trust, Harrow, UK.

    • Emma L Wakeling
  35. Neurology Department, Birmingham Children's Hospital, Birmingham, UK.

    • Evangeline Wassmer
  36. Academic Department of Paediatrics, Imperial College London, London, UK.

    • Elizabeth Whittaker
  37. Department of Paediatric Neurology, Leeds General Infirmary, Leeds, UK.

    • John H Livingston
  38. Institute of Structural and Molecular Biology, School of Biological Sciences, The University of Edinburgh, Edinburgh, UK.

    • Paul J McLaughlin
  39. Faculty of Life Sciences, University of Manchester, Manchester, UK.

    • Simon C Lovell

Authors

  1. Search for Gillian I Rice in:

  2. Search for Paul R Kasher in:

  3. Search for Gabriella M A Forte in:

  4. Search for Niamh M Mannion in:

  5. Search for Sam M Greenwood in:

  6. Search for Marcin Szynkiewicz in:

  7. Search for Jonathan E Dickerson in:

  8. Search for Sanjeev S Bhaskar in:

  9. Search for Massimiliano Zampini in:

  10. Search for Tracy A Briggs in:

  11. Search for Emma M Jenkinson in:

  12. Search for Carlos A Bacino in:

  13. Search for Roberta Battini in:

  14. Search for Enrico Bertini in:

  15. Search for Paul A Brogan in:

  16. Search for Louise A Brueton in:

  17. Search for Marialuisa Carpanelli in:

  18. Search for Corinne De Laet in:

  19. Search for Pascale de Lonlay in:

  20. Search for Mireia del Toro in:

  21. Search for Isabelle Desguerre in:

  22. Search for Elisa Fazzi in:

  23. Search for Àngels Garcia-Cazorla in:

  24. Search for Arvid Heiberg in:

  25. Search for Masakazu Kawaguchi in:

  26. Search for Ram Kumar in:

  27. Search for Jean-Pierre S-M Lin in:

  28. Search for Charles M Lourenco in:

  29. Search for Alison M Male in:

  30. Search for Wilson Marques in:

  31. Search for Cyril Mignot in:

  32. Search for Ivana Olivieri in:

  33. Search for Simona Orcesi in:

  34. Search for Prab Prabhakar in:

  35. Search for Magnhild Rasmussen in:

  36. Search for Robert A Robinson in:

  37. Search for Flore Rozenberg in:

  38. Search for Johanna L Schmidt in:

  39. Search for Katharina Steindl in:

  40. Search for Tiong Y Tan in:

  41. Search for William G van der Merwe in:

  42. Search for Adeline Vanderver in:

  43. Search for Grace Vassallo in:

  44. Search for Emma L Wakeling in:

  45. Search for Evangeline Wassmer in:

  46. Search for Elizabeth Whittaker in:

  47. Search for John H Livingston in:

  48. Search for Pierre Lebon in:

  49. Search for Tamio Suzuki in:

  50. Search for Paul J McLaughlin in:

  51. Search for Liam P Keegan in:

  52. Search for Mary A O'Connell in:

  53. Search for Simon C Lovell in:

  54. Search for Yanick J Crow in:

Contributions

G.I.R. performed quantitative PCR analysis. P.R.K. performed protein blot analysis. G.M.A.F. performed cell culture and interferon stimulation experiments with assistance from G.I.R. and T.A.B. M.S. performed Sanger sequencing with assistance from M.Z., G.M.A.F. and E.M.J. G.I.R. analyzed sequence data. M.S. and G.M.A.F. undertook microsatellite genotyping. J.E.D. and S.S.B. undertook analysis of the exome sequence data. J.H.L. was responsible for neuroradiological phenotyping. P.L. and F.R. measured interferon activity in affected individuals. M.A.O., L.P.K., S.M.G. and N.M.M. carried out ADAR1 editing assays. T.S. and M.K. provided the DSH RNA samples. S.C.L. and P.J.M. carried out ADAR1 structural analysis. Y.J.C. designed and supervised the project and wrote the manuscript with support from G.I.R. C.A.B., R.B., E.B., P.A.B., L.A.B., M.C., C.D.L., P.d.L., M.d.T., I.D., E.F., A.G.-C., A.H., R.K., J.-P.S.-M.L., C.M.L., A.M.M., W.M., C.M., I.O., S.O., P.P., M.R., R.A.R., J.L.S., K.S., T.Y.T., W.G.v.d.M., A.V., G.V., E.L.W., E. Wassmer and E. Whittaker identified subjects with AGS or assisted with related clinical and laboratory studies.

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Yanick J Crow.

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Figures 1–3 and Supplementary Tables 1–8

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/ng.2414

Further reading